Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia |
| |
Authors: | Gribben John G Zahrieh David Stephans Katherine Bartlett-Pandite Lini Alyea Edwin P Fisher David C Freedman Arnold S Mauch Peter Schlossman Robert Sequist Lecia V Soiffer Robert J Marshall Blossom Neuberg Donna Ritz Jerome Nadler Lee M |
| |
Affiliation: | Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. john.gribben@cancer.org.uk |
| |
Abstract: | We report here on the long-term follow-up on 162 patients with high-risk chronic lymphocytic leukemia (CLL) who have undergone hematopoietic stem cell transplantation (SCT) at a single center from 1989 to 1999. Twenty-five patients with human leukocyte antigen (HLA)-matched sibling donors underwent T-cell-depleted allogeneic SCT, and 137 patients without HLA-matched sibling donors underwent autologous SCT. The 100-day mortality was 4% for both groups, but later morbidity and mortality were negatively affected on outcome. Progression-free survival was significantly longer following autologous than allogeneic SCT, but there was no difference in overall survival and no difference in the cumulative incidence of disease recurrence or deaths without recurrence between the 2 groups. At a median follow-up of 6.5 years there is no evidence of a plateau of progression-free survival. The majority of patients treated with donor lymphocyte infusions after relapse responded, demonstrating a significant graft-versus-leukemia effect in CLL. From these findings we have altered our approach for patients with high-risk CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced-intensity conditioning regimens. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
| 点击此处可从《Blood》浏览原始摘要信息 |
|
点击此处可从《Blood》下载全文 |
|